High-dose prednisolone and psoralen ultraviolet A combination therapy in 36 patients with vitiligo.
It is well known that systemic corticosteroids arrest the progress of vitiligo and lead to repigmentation, but they may produce unacceptable side-effects. The use of high-dose prednisolone therapy to minimize the side-effects of systemic steroids has been reported, but there have been no reports on the effectiveness of such treatment combined with phototherapy. We evaluated the efficacy and safety of combination therapy with intravenous prednisolone and psoralen ultraviolet A (PUVA). In 36 patients with vitiligo, intravenous methylprednisolone for 3 days was followed by PUVA twice weekly. After 6 months, vitiligo lesions on the face were reduced in size by 57.5%, on the upper extremities by 34.5%, on the trunk by 30.4% and on the lower extremities by 26.3%. Overall, improvement was seen in 13 patients (36.1%), with >50% repigmentation. Side-effects were mild and transient. We conclude that combination treatment of high-dose prednisolone therapy and PUVA may represent a highly effective therapeutic option for generalized vitiligo.
Lee
Y
Y
Department of Dermatology, Chungnam National University School of Medicine, Daejeon, Korea.
Seo
Y J
YJ
Lee
J H
JH
Park
J K
JK
D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D005363:Ficusin / Q000008:administration & dosage; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011701:PUVA Therapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage*; D014820:Vitiligo / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D017319:Photosensitizing Agents; D011239:Prednisolone; D005363:Ficusin